Journal of Cancer Prevention最新文献

{"title":"Risk of Lung Cancer and Risk Factors of Lung Cancer in People Infected with Tuberculosis.","authors":"Sunghee Hong, Jihye Kim, Kunhee Park, Boyoung Park, Bo Youl Choi","doi":"10.15430/JCP.24.016","DOIUrl":"10.15430/JCP.24.016","url":null,"abstract":"<p><p>This study investigated lung cancer risk in people infected with tuberculosis (TB) compared to the general population and evaluated factors associated with lung cancer in TB-infected individuals. Mandatory reported TB infection case data in Gyeonggi Province, South Korea (2010 to 2016) were obtained and linked with medical usage and health screening data from the National Health Information Database. Lung cancer incidence in patients with TB was compared to that in the general population using standardized incidence ratio (SIR), adjusted for age and sex. Lung cancer risk factors in patients with TB were studied using the Cox proportional hazards model. By April 2022, 1.26% (n = 444) of 35,140 patients developed lung cancer after TB diagnosis. Compared to the incidence in the general population, increased lung cancer risk in people with TB was observed (SIR: 2.04, 95% CI: 1.85-2.23). Multivariate analysis showed increased lung cancer in TB-infected individuals, associated with being male (hazard ratio [HR]: 2.24, 95% CI: 1.65-3.04), 1-year increase of age (HR: 1.09, 95% CI: 1.08-1.10), ever smoking (HR: 1.42, 95% CI: 1.02-1.97), and amount of daily smoking with one pack or more (HR: 2.17, 95% CI: 1.63-2.89). Increased lung cancer risk was noted in patients with TB compared to the general population, and sex, age, and smoking were factors associated with lung cancer in patients with TB.</p>","PeriodicalId":15120,"journal":{"name":"Journal of Cancer Prevention","volume":"29 4","pages":"157-164"},"PeriodicalIF":2.5,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11706730/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142949399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship between Cancer Incidence and Health Behaviors from Ecological Study in Korea.","authors":"Kwang-Pil Ko","doi":"10.15430/JCP.24.025","DOIUrl":"10.15430/JCP.24.025","url":null,"abstract":"<p><p>The aim of this ecological study was to examine the correlation between cancer incidence and health behaviors such as smoking, alcohol consumption, and obesity, and investigated whether there were differences in this correlation between metropolitan areas and other regions. Data on health behaviors exposure/prevalence and cancer incidence rates for 227 administrative districts (cities and counties) were obtained. The average exposure proportion measured annually from 2008 to 2011 in the Korea Community Health Survey data and the age-standardized cancer incidence data from 2014 to 2018, obtained through the cancer registry data, were downloaded from the Statistics Korea website. To examine the relationship between smoking, alcohol consumption, obesity exposure rate (prevalence), and cancer incidence, a correlation analysis was conducted, and Pearson's correlation coefficient was calculated. The correlation coefficient between male smoking and male cancer incidence rate across 227 districts was 0.259. This significance was more pronounced in large metropolitan areas, where the correlation coefficient was 0.631 in the 73 districts belonging to these areas. In large metropolitan areas, the correlation coefficient between alcohol consumption rate and cancer incidence rate was 0.390. In the correlation analysis between obesity prevalence and cancer incidence rate, no correlation was found in large metropolitan areas, while in areas outside of large cities, the correlation coefficient was -0.295, indicating a significant negative correlation. This ecological study demonstrated that the relationship between cancer incidence and health behaviors differed between large metropolitan areas and areas outside of large cities.</p>","PeriodicalId":15120,"journal":{"name":"Journal of Cancer Prevention","volume":"29 4","pages":"185-189"},"PeriodicalIF":2.5,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11706724/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142949397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of Translocon-associated Protein Delta as An Oncogene in Human Colorectal Cancer Cells.","authors":"Darshika Amarakoon, Wu-Joo Lee, Jing Peng, Seong-Ho Lee","doi":"10.15430/JCP.24.014","DOIUrl":"10.15430/JCP.24.014","url":null,"abstract":"<p><p>Identifying the roles of genes in cancer is critical in discovering potential genetic therapies for cancer care. Translocon-associated protein delta (TRAPδ), also known as signal sequence receptor 4 (SSR4), is a constituent unit in the TRAP/SSR complex that resides in the endoplasmic reticulum and plays a key role in transporting newly synthesized proteins into the endoplasmic reticulumn. However, its biological role in disease development remains unknown to date. This is the first study to identify the role of TRAPδ/SSR4 in colorectal cancer cells in vitro. Upon successful transient knockdown of <i>TRAPδ/SSR4</i>, we observed significant reduction of cell viability in all colorectal cancer cell lines tested. Both HCT 116 and SW480 cell lines were significantly arrested at S and G1 phases, while DLD-1 cells were significantly apoptotic. Moreover, <i>TRAPδ/SSR4</i> stable knockdown HCT 116 and SW480 cells showed significantly lower viability, anchorage-independent growth, and increased S and G1 phase arrests. Overall, we conclude <i>TRAPδ/SSR4</i> is a potential oncogene in human colorectal cancer cells.</p>","PeriodicalId":15120,"journal":{"name":"Journal of Cancer Prevention","volume":"29 4","pages":"175-184"},"PeriodicalIF":2.5,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11706732/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142949394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evolving Therapeutic Strategies in Esophageal Squamous Cell Carcinoma: Advances and Perspectives.","authors":"Zhibin Liu, Myoung Ok Kim","doi":"10.15430/JCP.24.026","DOIUrl":"10.15430/JCP.24.026","url":null,"abstract":"<p><p>Esophageal squamous cell carcinoma (ESCC) is among the most prevalent forms of esophageal cancer globally, with a particularly high incidence in developing countries. Notably, Asia accounts for approximately 80% of global esophageal cancer cases, with China alone contributing to 54% of this burden. The primary treatment modality for ESCC remains esophagectomy, primarily employed for locally advanced disease, often in combination with chemotherapy and radiotherapy for advanced-stage cases. Despite significant advancements in surgical techniques and the advent of precision medicine, which has facilitated the development of targeted and immune-based therapies, critical challenges persist, including suboptimal therapeutic efficacy and the emergence of drug resistance. A comprehensive understanding of the current treatment landscape for ESCC is essential to overcoming these barriers and improving patient outcomes.</p>","PeriodicalId":15120,"journal":{"name":"Journal of Cancer Prevention","volume":"29 4","pages":"99-104"},"PeriodicalIF":2.5,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11706721/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142949393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Challenges in Metabolite Biomarkers as Avenues of Diagnosis and Prognosis of Cancer.","authors":"Nilesh Kumar Sharma, Sachin C Sarode, Gopinath Sekar, Kaveri Sonawane, Dhanashree Bomle","doi":"10.15430/JCP.24.015","DOIUrl":"10.15430/JCP.24.015","url":null,"abstract":"<p><p>Given the evolutionary nature of tumor complexities and heterogeneity, the early diagnosis of cancer encounters various challenges. Complexities at the level of metabolite reprogramming are compelling in the background of invasiveness, metastasis, drug- and radiation-induced metabolic alterations, immunotherapy-influenced changes, and pro-tumor niche including microbiome. Therefore, it is crucial to examine both current and future obstacles associated with early cancer detection specifically in the context of tumor metabolite biomarkers at preclinical and clinical levels. In conclusion, the significance of tumor metabolite biomarkers must be aligned with a comprehensive approach to achbieve diagnosis and prognosis of cancer patients by securing solutions to formidable challenges.</p>","PeriodicalId":15120,"journal":{"name":"Journal of Cancer Prevention","volume":"29 4","pages":"105-112"},"PeriodicalIF":2.5,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11706722/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142949391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of GastroPanel^® and GENEDIA^® in Diagnosing <i>Helicobacter pylori</i> Infection and Gastric Lesions.","authors":"Yonghoon Choi, Nayoung Kim, Seon Hee Lim, Ji Hyun Park, Jeong Hwan Lee, Yeejin Kim, Hyemin Jo, Ho-Kyoung Lee, Jinju Choi, Yu Kyung Jun, Hyuk Yoon, Cheol Min Shin, Young Soo Park, Dong Ho Lee","doi":"10.15430/JCP.24.024","DOIUrl":"10.15430/JCP.24.024","url":null,"abstract":"<p><p>Serological tests for <i>Helicobacter pylori</i> needs local validation as the diagnostic accuracy may vary depending on the prevalence of <i>H</i>. <i>pylori</i>. This study examined the diagnostic performance of two ELISA, GastroPanel^® (GastroPanel ELISA; Biohit Oyj) and GENEDIA^® (GENEDIA^® <i>H</i>. <i>pylori</i> ELISA, Green Cross Co.) in Korean population. One thousand seventy seven patients who visited for esophagogastroduodenoscopy between 2013 and 2023 were prospectively enrolled, and serum samples from the subjects were tested using both GastroPanel^® and GENEDIA^®. The two tests were compared for their diagnostic accuracy in detecting atrophic gastritis (AG), intestinal metaplasia (IM), gastric adenoma (GA), and gastric cancer (GC), and the positivity rates by age and sex were observed. There was substantial correlation (Pearson coefficient [r] = 0.512, <i>P</i> < 0.001) and agreement (Cohen's Kappa coefficient [κ] = 0.723, <i>P</i> < 0.001) between the results obtained using GastroPanel^® and GENEDIA^®. The test results from the two kits did not match perfectly with a discrepancy observed in approximately 16% of cases, that 67 subjects were positive only on GENEDIA^® while 75 subjects were positive only on GastroPanel^®. The area under receiver operating characteristic curve for AG, IM, GA, and GC using GastroPanel^® were 0.666, 0.635, 0.540, and 0.575, while the results tested using GENEDIA^® were 0.649, 0.604, 0.553, and 0.555, respectively, without significant difference between the two results. GastroPanel^® and GENEDIA^® showed similar performance in terms of diagnostic accuracy; but the test results did not match perfectly. A large-scale validation study in Koreans is needed.</p>","PeriodicalId":15120,"journal":{"name":"Journal of Cancer Prevention","volume":"29 4","pages":"148-156"},"PeriodicalIF":2.5,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11706727/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142949392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Shiga Toxin: Emerging Producer Strains, Prophylactic Approaches, and Application in Cancer Therapy.","authors":"Kiandokht Babolhavaeji, Amjad Ahmadi, Leili Shokoohizadeh","doi":"10.15430/JCP.24.010","DOIUrl":"10.15430/JCP.24.010","url":null,"abstract":"<p><p>Shiga toxin-producing <i>Escherichia coli</i> is the most prevalent bacterial strain responsible for Shiga toxin-related infections. While Shiga toxin is inherently toxic, it has potential therapeutic applications as a component of anticancer drugs. Despite its association with infections and harmful effects on human health, Shiga toxin is being explored as a viable element in drug delivery systems targeting cancer cells. The findings indicate that the production of mutated bacteria containing Shiga toxin is an effective preventive strategy for immunization against these toxins. Furthermore, the B subunit of Shiga toxin shows promise for imaging cancer cells, opening new paths for therapeutic interventions.</p>","PeriodicalId":15120,"journal":{"name":"Journal of Cancer Prevention","volume":"29 4","pages":"120-128"},"PeriodicalIF":2.5,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11706725/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142949400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Kaempferol Synergistically Enhances Cisplatin-induced Apoptosis and Cell Cycle Arrest in Colon Cancer Cells.","authors":"Muhammad Haroon, Sun Chul Kang","doi":"10.15430/JCP.24.013","DOIUrl":"https://doi.org/10.15430/JCP.24.013","url":null,"abstract":"<p><p>Colon cancer remains a significant global health concern, necessitating the continuous exploration of novel therapeutic strategies. Cisplatin is a first-line chemotherapy medication that is frequently used to treat patients for a variety of malignancies, including colon cancer. However, a major obstacle to its clinical usefulness is acquired resistance. This research investigates the synergistic effects of kaempferol, a natural flavonoid with known anti-cancer properties, in combination with cisplatin, in colon cancer cells. Our study employed colon cancer cell lines to evaluate the individual and combined cytotoxic effects of kaempferol and cisplatin. The results demonstrated a notable enhancement in the cytotoxicity of colon cancer cells when treated with a combination of kaempferol and cisplatin compared to individual treatments. This synergistic effect was further characterized by an increase in apoptosis, as evidenced by morphological changes and biochemical markers of apoptosis and cell cycle. The investigations revealed that the combined treatment led to the modulation of key apoptotic pathways, including the upregulation of pro-apoptotic factors and downregulation of anti-apoptotic factors. Additionally, the synergistic effect was associated with the inhibition of cell proliferation and induction of cell cycle arrest. The findings of this study suggest that the combination of kaempferol and cisplatin holds promise as a potent therapeutic strategy for colon cancer treatment, potentially enhancing the efficacy of conventional chemotherapy while minimizing adverse effects. Further in-depth investigations, including in vivo studies, are warranted to validate these findings and explore the translational potential of this synergistic approach in clinical settings.</p>","PeriodicalId":15120,"journal":{"name":"Journal of Cancer Prevention","volume":"29 3","pages":"69-87"},"PeriodicalIF":2.5,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11467758/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142466200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recommendations for Healthy Lifestyle for Cancer Prevention and Healthy Aging.","authors":"Omer Kucuk, Viraj A Master","doi":"10.15430/JCP.24.018","DOIUrl":"https://doi.org/10.15430/JCP.24.018","url":null,"abstract":"","PeriodicalId":15120,"journal":{"name":"Journal of Cancer Prevention","volume":"29 3","pages":"55-57"},"PeriodicalIF":2.5,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11467757/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142466201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anticancer Activity of Phytochemicals of the Papaya Plant Assessed: A Narrative Review.","authors":"Shachi Patel, Karankumar Rana, Param Arya, Janelle Nelson, Vanesa Hernandez, Victoria Minakova","doi":"10.15430/JCP.24.020","DOIUrl":"https://doi.org/10.15430/JCP.24.020","url":null,"abstract":"<p><p>Cancer remains to be a pervasive disease as traditional treatments have plateaued in efficacy. Anticancer research continues to grow in an effort to find novel preventive and treatment measures for cancers. The papaya plant produces several biologically active phytochemicals, which exhibit anti-inflammatory, antibacterial, and anti-oxidative properties. This review explores studies examining these phytochemicals derived from the papaya plant as a potential chemopreventive agent and a cancer therapeutic. Further studies must be done to establish the papaya plant and its phytochemicals as an alternative to traditional cancer treatments.</p>","PeriodicalId":15120,"journal":{"name":"Journal of Cancer Prevention","volume":"29 3","pages":"58-68"},"PeriodicalIF":2.5,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11467756/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142466199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}